Orforglipron
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Eli Lilly · Phase 1 · Recruiting · Enrollment 104
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Investigational Drug: IBI3042 (Part A) | n/r | n/r | n/r | n/r |
| Investigational Drug: IBI3042 (Part B) | n/r | n/r | n/r | n/r |
| Matching Placebo (Part B) | n/r | n/r | n/r | n/r |
| Orforglipron (Part B) | n/r | n/r | n/r | n/r |
| Matching Placebo (Part A) | n/r | n/r | n/r | n/r |
Not shown
- Investigational Drug: IBI3042 (Part A): endpoint not reported
- Investigational Drug: IBI3042 (Part B): endpoint not reported
- Matching Placebo (Part B): endpoint not reported
- Orforglipron (Part B): endpoint not reported
- Matching Placebo (Part A): endpoint not reported